<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Osteoporosis. In: Guidelines for preventive activities in general practice, 8th edition.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Osteoporosis. In: Guidelines for preventive activities in general practice, 8th edition. East Melbourne (Australia): Royal Australian College of General Practitioners; 2012. p. 82-4.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Bone mineral density studies  (88.98); Fracture, cause unspecified  (E887); Osteoporosis, unspecified  (733.00); Pathologic fracture, unspecified site  (733.10); Pathologic fracture, unspecified site  (V13.51)"/><FieldValue Value="MSH: Absorptiometry, Photon ; Accident Prevention ; Accidental Falls ; Bone Density ; Calcium, Dietary ; Exercise ; Fractures, Bone ; Fractures, Spontaneous ; General Practice ; Health Promotion ; Life Style ; Medical History Taking ; Osteoporosis ; Osteoporosis, Postmenopausal ; Osteoporotic Fractures ; Patient Education as Topic ; Preventive Health Services ; Primary Health Care ; Risk Assessment ; Risk Factors ; Risk Management ; Risk Reduction Behavior ; Smoking Cessation ; Social Support "/><FieldValue Value="MTH: Accidental Falls ; Bone Density ; Bone Mineral Density Test ; Calcium, Dietary ; Cessation of smoking ; Exercise ; Fall prevention ; Fracture ; general practice (field) ; Life Style ; Osteoporosis ; Osteoporosis, Postmenopausal ; Pathological fracture ; Patient education (procedure) ; Primary Health Care ; Psychosocial assessment (procedure) ; Risk Assessment ; risk factors ; Social support "/><FieldValue Value="PDQ: osteoporosis "/><FieldValue Value="SNOMEDCT_US: Accident prevention  (134185000); Accidental fall  (217082002); Education about alcohol consumption  (281078001); Exercise  (183301007); Exercise  (256235009); Exercise  (61686008); Fall prevention  (386296001); Fracture  (125605004); Fracture  (72704001); General medicine  (394802001); Health promotion  (171434007); Life style  (134436002); Life style  (60134006); Osteoporosis  (64859006); Osteoporosis - falls prevention  (391027005); Osteoporosis risk assessment done  (391014006); Osteoporotic fracture  (46675001); Pathological fracture  (22640007); Pathological fracture  (268029009); Patient advised about exposure to the sun  (183079004); Patient education  (311401005); Postmenopausal osteoporosis  (102447009); Postmenopausal osteoporosis  (32369003); Psychosocial analysis assessment  (371585000); Psychosocial analysis assessment  (408920002); Risk assessment  (225338004); Risk factor  (80943009); Risk management  (225314003)"/><FieldValue Value="UMD: Densitometers, Bone, X-Ray, Dual-Energy Absorptiometry  (17-747)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Osteoporosis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Osteoporotic fractures &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Counseling" /><FieldValue Value="Prevention" /><FieldValue Value="Risk Assessment" /><FieldValue Value="Screening" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Family Practice" /><FieldValue Value="Geriatrics" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Obstetrics and Gynecology" /><FieldValue Value="Preventive Medicine" /><FieldValue Value="Rheumatology" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Health Care Providers" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /><FieldValue Value="Public Health Departments" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;To facilitate evidence-based preventive activities for osteoporosis in primary care &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To provide a comprehensive and concise set of recommendations for patients in general practice with additional information about tailoring risk and need &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To provide the evidence base for which primary healthcare resources can be used efficiently and effectively while providing a rational basis to ensure the best use of time and resources in general practice &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Australian women aged &amp;ge;45 years &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Australian men aged &amp;ge;50 years &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Assessment of risk factors for osteoporosis (thorough patient history) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Preventive advice&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Ensuring adequate calcium intake &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Encouraging healthy lifestyle (e.g., smoking cessation, limiting alcohol and caffeine) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Education and psychosocial support for risk factor modification &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Falls reduction strategies &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Encouraging exercise &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Advice on safe sun exposure levels &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Discussing absolute fracture risk &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Bone mineral density measured by dual-energy X-ray absorptiometry (DXA) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Management of risk factors &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Investigations for causes of secondary osteoporosis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Initiation of anti-osteoporotic therapy, if indicated &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Risk of fracture&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Hand-searches of Published Literature (Primary Sources)" /><FieldValue Value="Hand-searches of Published Literature (Secondary Sources)" /><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Sources of Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The recommendations in these guidelines are based on current, evidence-based guidelines for preventive activities. The Taskforce focused on those most relevant to Australian general practice. Usually this means that the recommendations are based on Australian guidelines such as those endorsed by the National Health and Medical Research Council (NHMRC).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In cases where these are not available or recent, other Australian sources have been used, such as guidelines from the Heart Foundation, Canadian or United States preventive guidelines, or the results of systematic reviews. References to support these recommendations are listed. However, particular references may relate to only part of the recommendation (e.g., only relating to one of the high-risk groups listed) and other references in the section may have been considered in formulating the overall recommendation.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Levels of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Levels of Evidence&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Level&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Explanation&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;I&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence obtained from a systematic review of level II studies&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;II&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence obtained from a randomised controlled trial (RCT)&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;III&amp;ndash;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence obtained from a pseudo-randomised controlled trial (i.e., alternate allocation or some other method)&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;III&amp;ndash;2&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence obtained from a comparative study with concurrent controls:&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Non-randomised, experimental trial &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Cohort study &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Case&amp;ndash;control study &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Interrupted time series with a control group &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;III&amp;ndash;3&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence obtained from a comparative study without concurrent controls:&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Historical control study &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Two or more single arm study &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Interrupted time series without a parallel control group &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;IV&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Case series with either post-test or pre-test/post-test outcomes&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Practice Point&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Opinions of respected authorities, based on clinical experience, descriptive studies or reports of expert committees&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review of Published Meta-Analyses" /><FieldValue Value="Systematic Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;These &lt;em&gt;Guidelines for preventive activities in general practice&lt;/em&gt;, 8th edition, have been developed by a taskforce of general practitioners (GPs) and experts to ensure that the content is the most valuable and useful for GPs and their teams. The guidelines provide an easy, practical and succinct resource. The content broadly conforms to the highest evidence-based standards according to the principles underlying the Appraisal of Guidelines Research and Evaluation.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The dimensions addressed are:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Scope and purpose &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Clarity of presentation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Rigour of development &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Stakeholder involvement &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Applicability &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Editorial independence &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;The Red Book maintains developmental rigour, editorial independence, relevance and applicability to general practice.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Screening Principles&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The World Health Organization (WHO) has produced guidelines for the effectiveness of screening programs. The Taskforce has kept these and the United Kingdom National Health Services' guidelines in mind in the development of recommendations about screening and preventive care.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Grades of Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Grades of Recommendations&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Grade&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Explanation&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Body of evidence can be trusted to guide practice&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;B&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Body of evidence can be trusted to guide practice in most situations&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;C&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Body of evidence provides some support for recommendation(s) but care should be taken in its application&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;D&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Body of evidence is weak and recommendation must be applied with caution&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The levels of evidence (&lt;strong&gt;I-IV, Practice Point&lt;/strong&gt;) and grades of recommendations (&lt;strong&gt;A-D&lt;/strong&gt;) are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Osteoporosis&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Review of fracture risk factors for women aged over 45 years and men aged over 50 years is recommended (&lt;strong&gt;C&lt;/strong&gt;). Those with increased risk should have bone density assessed (&lt;strong&gt;A&lt;/strong&gt;).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Osteoporosis is a disease characterised by low bone mass and micro-architectural deterioration of bone tissue, leading to bone fragility and increased fracture risk (National Health and Medical Research Council, 2010). It is diagnosed on the presence of a fragility fracture (fracture from the equivalent of a fall from standing height or less, or a fracture that under normal circumstances would not be expected in a healthy young man or woman). For epidemiological and clinical purposes, osteoporosis is defined by bone mineral density (BMD) as a T-score of &amp;le;-2.5. However, age, lifestyle factors, family history and some medications and diseases all contribute to bone loss and increased risk of fragility fractures. Thus, the goal of prevention and treatment is to reduce a person's overall fracture risk (not just bone density maintenance).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Methods to estimate absolute fracture risk for osteoporotic fractures are available at:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;a href=&quot;http://www.shef.ac.uk/FRAX&quot; title=&quot;FRAX Web site&quot;&gt;www.shef.ac.uk/FRAX&lt;/a&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;a href=&quot;http://garvan.org.au/promotions/bone-fracture-risk/calculator/&quot; title=&quot;Garvan Institute Web site&quot;&gt;http://garvan.org.au/promotions/bone-fracture-risk/calculator/&lt;/a&gt; &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;As bone densitometry is part of these estimates, BMD should be considered as part of the overall fracture risk assessment (&lt;strong&gt;D&lt;/strong&gt;). Risk estimation is imperfect, but the calculator's predictive performance is similar to absolute cardiovascular risk calculators (Nelson et al., 2010). Risk factors (e.g., falls, glucocorticoid use, etc.) not included in one or other risk algorithm require clinical judgement to modify the risk estimate.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;To date, there are no randomised controlled trials (RCT) directly evaluating screening effectiveness, harms and intervals, whether screening is performed by bone density screening by dual-energy X-ray absorptiometry (DXA) or by estimating absolute fracture risk. The place of absolute fracture risk assessment in the prevention and management of osteoporosis requires further clarification as its effectiveness is yet to be tested.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Osteoporosis: Identifying Risk&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Osteoporosis: Identifying Risk&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Who Is at Risk?&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;What Should Be Done?&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;How Often?&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;References&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;strong&gt;Average Risk&lt;/strong&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Postmenopausal women (aged 45 years or older) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Men aged 50 years or older &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Assessment for risk factors (&lt;strong&gt;II,C&lt;/strong&gt;) &lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            Preventive advice (&lt;strong&gt;II,C&lt;/strong&gt;)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Every 12 months (&lt;strong&gt;Practice Point&lt;/strong&gt;)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;National Health and Medical Research Council (NHMRC), 2010; Nelson et al., 2010&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;strong&gt;Increased Risk&lt;/strong&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Age &amp;gt;60 years for men and &amp;gt;50 years for women plus any of:&#xD;&#xA;                &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                    &lt;li&gt;Family history of fragility fracture &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Smoking &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;High alcohol intake (&amp;gt;2&amp;ndash;4 standard drinks per day for men, less for women) &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Vitamin D deficiency &amp;lt;60 nmol (screening for vitamin D not indicated just for risk assessment) &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Low body weight (body mass index [BMI] &amp;lt;20) &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Recurrent falls &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Low levels of physical activity &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Immobility (to the extent that person cannot leave their home or cannot do any housework) &lt;/li&gt;&#xD;&#xA;                &lt;/ul&gt;&#xD;&#xA;                &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Medical conditions and medications that may cause secondary osteoporosis:&#xD;&#xA;                &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                    &lt;li&gt;Endocrine (e.g., hypogonadism, Cushing syndrome, hyperparathyroidism, hyperthyroidism) &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Inflammatory conditions (e.g., rheumatoid arthritis) &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Malabsorption (e.g., coeliac) &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Chronic kidney disease (CKD), chronic liver disease &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Drugs, especially corticosteroids (e.g., 7.5 mg x 3 months) used for immunosuppression including as part of chronic anti-rejection therapy in organ or bone marrow transplant, antiepileptic, aromatase inhibitors, anti-androgen, excessive thyroxine, possibly selective serotonin reuptake inhibitors (also known as SSRIs) &lt;/li&gt;&#xD;&#xA;                &lt;/ul&gt;&#xD;&#xA;                &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Bone mineral densitometry (BMD) and management of risk factors (&lt;strong&gt;II,A&lt;/strong&gt;) &lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            Investigate for causes of secondary osteoporosis if indicated by history, examination findings or BMD result (&lt;strong&gt;Practice Point&lt;/strong&gt;).&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;At presentation and no more than every 2 years. Repeat when it is likely to change management (&lt;strong&gt;II,C&lt;/strong&gt;). &lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            Where there is a specific bone mineral wasting condition or medication, consider more frequent repeat of dual-energy X-ray absorptiometry (DXA) if likely to change treatment (&lt;strong&gt;Practice Point&lt;/strong&gt;).&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;U.S. Preventive Services Task Force, 2011; Nakamura et al., 2012&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;strong&gt;High Risk of Further Fracture&lt;/strong&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Patients aged over 45 years who sustain a low trauma fracture &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Postmenopausal women, and men with a suspected vertebral fracture (loss of height &amp;gt;3 cm, kyphosis, back pain) &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;BMD and management of risk factors (&lt;strong&gt;II,A&lt;/strong&gt;) &lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            Investigate for causes of secondary osteoporosis if indicated by history, examination findings or BMD result (&lt;strong&gt;Practice Point&lt;/strong&gt;).&lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            Recommend that such individuals are initiated on effective anti-osteoporosis therapy unless there are specific contraindications.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;DXA at presentation and no more than every 2 years (&lt;strong&gt;II,B&lt;/strong&gt;) &lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            Repeat only when it is likely to change management &lt;br /&gt;&#xD;&#xA;            (&lt;strong&gt;Practice Point&lt;/strong&gt;). &lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            Where there is a specific bone mineral wasting condition or medication, consider more frequent repeat of DXA (&lt;strong&gt;Practice Point&lt;/strong&gt;).&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;NHMRC, 2010&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Osteoporosis: Preventive Interventions&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Test to Detect Depression&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Intervention&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Technique&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;References&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Assessment of risk factors&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Take a thorough history, paying particular attention to the risk factors above plus:&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Vertebral deformity (if within 5&amp;ndash;10 years, this is equivalent risk as any other fragility fracture) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Loss of height (&amp;gt;3 cm) and/or thoracic kyphosis (consider lateral spine X-ray for vertebral deformity) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Premature menopause &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Anorexia nervosa or amenorrhea for greater than 12 months before age 45 years &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Preventive actions&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Ensure adequate daily calcium intake: dietary calcium ([&lt;strong&gt;A&lt;/strong&gt;] for prevention of bone loss, [&lt;strong&gt;C&lt;/strong&gt;] for fracture) 1,200 mg/day. Exercise caution with supplements.* &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Encourage healthy lifestyle (e.g., smoking cessation and limiting alcohol and caffeine intake). (&lt;strong&gt;D&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Education and psychosocial support for risk factor modification (&lt;strong&gt;Practice Point&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Falls reduction strategies: for fracture risk reduction (&lt;strong&gt;Practice Point&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Encourage exercise: for prevention of bone loss (&lt;strong&gt;A&lt;/strong&gt;) and fracture risk reduction (&lt;strong&gt;Practice Point&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Advise on safe sun exposure levels as a source of vitamin D.&amp;dagger; (&lt;strong&gt;II,C&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Discuss absolute risk of fracture. (&lt;strong&gt;Practice Point&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Bone mineral densitometry (BMD)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;BMD should be measured by dual-energy X-ray absorptiometry (DXA) scanning performed on 2 sites, preferably anteroposterior spine and hip. Without bone-losing medical conditions (e.g., steroid use), it is unlikely to change significantly in less than 2 years (&lt;strong&gt;II,B&lt;/strong&gt;) and DXA should generally be repeated only when patient is at risk of reaching treatment thresholds (average decrease in T-score is usually approx 0.1/year if no specific bone-losing medical conditions) (&lt;strong&gt;Practice Point&lt;/strong&gt;). Rate of bone loss tends to be slower in early older age (60+) than in later old age (80+), and slower in men than women.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Frost et al., 2009&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;*Controversial level II evidence of increased risk of cardiovascular events with calcium supplements in postmenopausal women, not seen in dietary studies (Bolland et al., 2008; Bolland, 2010; Lewis et al., 2011).&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&amp;dagger;Population screening for vitamin D deficiency is not recommended, but targeted testing of people who are at risk of osteoporosis and who are at high risk of vitamin D deficiency should be considered. Vitamin D supplements could be considered in deficient individuals if increasing sun exposure is contraindicated or not feasible or if deficiency is more than mild (i.e., &amp;lt;25 nmol/L) and so is less likely to be corrected by safe sun exposure (Winzenberg et al., 2012) (&lt;strong&gt;Practice Point&lt;/strong&gt;).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Levels of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Levels of Evidence&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Level&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Explanation&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;I&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence obtained from a systematic review of level II studies&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;II&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence obtained from a randomised controlled trial (RCT)&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;III&amp;ndash;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence obtained from a pseudo-randomised controlled trial (i.e., alternate allocation or some other method)&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;III&amp;ndash;2&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence obtained from a comparative study with concurrent controls:&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Non-randomised, experimental trial &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Cohort study &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Case&amp;ndash;control study &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Interrupted time series with a control group &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;III&amp;ndash;3&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence obtained from a comparative study without concurrent controls:&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Historical control study &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Two or more single arm study &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Interrupted time series without a parallel control group &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;IV&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Case series with either post-test or pre-test/post-test outcomes&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Practice Point&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Opinions of respected authorities, based on clinical experience, descriptive studies or reports of expert committees&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Grades of Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Grades of Recommendations&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Grade&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Explanation&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Body of evidence can be trusted to guide practice&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;B&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Body of evidence can be trusted to guide practice in most situations&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;C&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Body of evidence provides some support for recommendation(s) but care should be taken in its application&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;D&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Body of evidence is weak and recommendation must be applied with caution&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="98" OrdBy="605" ID="425" Name="References Supporting the Recommendations" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Bolland MJ, Avenell A, Baron JA, Grey A, MacLennan GS, Gamble GD, Reid IR. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ. 2010;341:c3691. [58 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20671013&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Bolland MJ, Barber PA, Doughty RN, Mason B, Horne A, Ames R, Gamble GD, Grey A, Reid IR. Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. BMJ. 2008 Feb 2;336(7638):262-6. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18198394&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Frost SA, Nguyen ND, Center JR, Eisman JA, Nguyen TV. Timing of repeat BMD measurements: development of an absolute risk-based prognostic model. J Bone Miner Res. 2009 Nov;24(11):1800-7. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19419321&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Lewis JR, Calver J, Zhu K, Flicker L, Prince RL. Response to 'calcium supplements and cardiovascular risk'. J Bone Miner Res. 2011;26(4):900-1.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Nakamura T, Tsujimoto M, Hamaya E, Sowa H, Chen P. Consistency of fracture risk reduction in Japanese and Caucasian osteoporosis patients treated with teriparatide: a meta-analysis. J Bone Miner Metab. 2012 May;30(3):321-5. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21938382&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;National Health and Medical Research Council. Clinical guideline for the prevention and treatment of osteoporosis in postmenopausal women and older men. South Melbourne, Victoria: Royal Australian College of General Practitioners; 2010 Feb. 83 p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Nelson HD, Haney EM, Chou R, Dana T, Fu R, Bougatsos C. Screening for osteoporosis: systematic review to update the 2002 U.S. Preventive Services Task Force recommendation. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ); 2010 Jul. &amp;nbsp;(Evidence Syntheses; no. 77).&amp;nbsp; &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20722176&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;U.S. Preventive Services Task Force. Screening for osteoporosis: clinical summary of U.S. Preventive Services Task Force Recommendation. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ); 2011. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Winzenberg T, van der Mei I, Mason RS, Nowson C, Jones G. Vitamin D and the musculoskeletal health of older adults. Aust Fam Physician. 2012 Mar;41(3):92-9. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22396920&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for selected recommendations (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The goal of prevention and treatment is to reduce a person's overall fracture risk (not just bone density maintenance). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Those with a previous fragility fracture have a very high risk of further fracture, and have greatest benefit from specific anti-osteoporosis treatment. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The information set out in this publication is current at the date of first publication and is intended for use as a guide of a general nature only and may or may not be relevant to particular patients or circumstances. Nor is this publication exhaustive of the subject matter. Persons implementing any recommendations contained in this publication must exercise their own independent skill or judgement or seek appropriate professional advice relevant to their own particular circumstances when so doing. Compliance with any recommendations cannot of itself guarantee discharge of the duty of care owed to patients and others coming into contact with the health professional and the premises from which the health professional operates. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Whilst the text is directed to health professionals possessing appropriate qualifications and skills in ascertaining and discharging their professional (including legal) duties, it is not to be regarded as clinical advice and, in particular, is no substitute for a full examination and consideration of medical history in reaching a diagnosis and treatment based on accepted clinical practices. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Accordingly, the Royal Australian College of General Practitioners and its employees and agents shall have no liability (including without limitation liability by reason of negligence) to any users of the information contained in this publication for any loss or damage (consequential or otherwise), cost or expense incurred or arising by reason of any person using or relying on the information contained in this publication and whether caused by reason of any error, negligent act, omission or misrepresentation in the information. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;These guidelines have not included detailed information on the management of risk factors or early disease (e.g., what medications to use in treating hypertension). Similarly, they have not made recommendations about tertiary prevention (preventing complications in those with established disease). Also, information about prevention of infectious diseases has been limited largely to immunisation and some sexually transmitted infections (STIs). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;For preventive care to be most effective, it needs to be planned, implemented and evaluated. Planning and engaging in preventive health is increasingly expected by patients. The Royal Australian College of General Practitioners (RACGP) thus provides the Red Book and &lt;em&gt;National guide to inform evidence-based guidelines&lt;/em&gt;, and the Green Book (see the &quot;Availability of Companion Documents&quot; field) to assist in development of programs of implementation. The RACGP is planning to introduce a small set of voluntary clinical indicators to enable practices to monitor their preventive activities.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Chart Documentation/Checklists/Forms" /><FieldValue Value="Resources" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Staying Healthy" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Osteoporosis. In: Guidelines for preventive activities in general practice, 8th edition. East Melbourne (Australia): Royal Australian College of General Practitioners; 2012. p. 82-4.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This guideline has been partially adapted from Australian, Canadian, United Kingdom, and/or United States preventive guidelines.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2012" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="Royal Australian College of General Practitioners - Professional Association" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Royal Australian College of General Practitioners&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Red Book Taskforce&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Taskforce Members&lt;/em&gt;: Dr Evan Ackermann (&lt;em&gt;Chair&lt;/em&gt;), Chair, National Standing Committee for Quality Care, RACGP; Professor Mark Harris, Centre for Primary Health Care and Equity, University of New South Wales, National Standing Committee for Quality Care, RACGP; Dr Karyn Alexander, General practitioner, Victoria; Dr Meredith Arcus, General practitioner, Western Australia; Linda Bailey, Project Manager, Red Book Taskforce; Dr John Bennett, Chair, National Standing Committee for e-Health, RACGP; Associate Professor Pauline Chiarelli, School of Health Sciences, University of Newcastle, New South Wales; Professor Chris Del Mar, Faculty of Health Sciences and Medicine, Bond University, Queensland; Professor Jon Emery, School of Primary, Aboriginal and Rural Health Care, The University of Western Australia, National Standing Committee for Research, RACGP; Dr Ben Ewald, School of Medicine and Public Health, University of Newcastle, New South Wales; Dr Dan Ewald, General practitioner, New South Wales, Adjunct Associate Professor, Northern Rivers University Centre for Rural Health, and Clinical Advisor North Coast NSW Medicare Local; Professor Michael Fasher, Adjunct Associate Professor, University of Sydney, and Conjoint Associate Professor, University of Western Sydney, New South Wales; Dr John Furler, Department of General Practice, The University of Melbourne, Victoria; Dr Faline Howes, General practitioner, Tasmania; Dr Caroline Johnson, Department of General Practice, The University of Melbourne, Victoria, National Standing Committee for Quality Care, RACGP; Dr Beres Joyner, General practitioner, Queensland; Associate Professor John Litt, Department of General Practice, Flinders University, South Australia, Deputy Chair, National Standing Committee for Quality Care, RACGP; Professor Danielle Mazza, Department of General Practice, School of Primary Care, Monash University, Victoria, National Standing Committee for Quality Care, RACGP; Professor Dimity Pond, School of Medicine and Public Health, University of Newcastle, New South Wales; Associate Professor Lena Sanci, Department of General Practice, The University of Melbourne, Victoria; Associate Professor Jane Smith, Faculty of Health Sciences and Medicine, Bond University, Queensland; Dr Tania Winzenberg, Deputy Chair, National Standing Committee for Research, RACGP&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.racgp.org.au/your-practice/guidelines/redbook/&quot; title=&quot;Royal Australian College of General Practitioners (RACGP) Web site&quot;&gt;Royal Australian College of General Practitioners (RACGP) Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following are available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Preventive activities over the lifecycle &amp;ndash; adults. Preventive activities over the lifecycle &amp;ndash; children. Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.racgp.org.au/download/Documents/Guidelines/Redbook8/redbook8_charts.pdf&quot; title=&quot;Royal Australian College of General Practitioners (RACGP) Web site&quot;&gt;Royal Australian College of General Practitioners (RACGP) Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Putting prevention into practice (green book). East Melbourne (Australia): Royal Australian College of General Practitioners; 2006. 104 p. Electronic copies: Available in PDF from the &lt;a href=&quot;http://www.racgp.org.au/your-practice/guidelines/greenbook/&quot; title=&quot;Royal Australian College of General Practitioners (RACGP) Web site&quot;&gt;RACGP Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;National guide to a preventive health assessment for Aboriginal and Torres Strait Islander people. East Melbourne (Australia): Royal Australian College of General Practitioners; 2012. 100 p. Electronic copies: Available in PDF from the &lt;a href=&quot;http://www.racgp.org.au/your-practice/guidelines/national-guide/&quot; title=&quot;Royal Australian College of General Practitioners (RACGP) Web site&quot;&gt;RACGP Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on May 31, 2013.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
